PROTAGONIST THERAPEUTICS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-95.6% -$163M
$7M
R&D↑+32.8% +$11M
$46M
D&A↑+218.6% +$258K
$376K
Operating Income↓-12.0% -$5M
$-46M
EBITDA↓-99.7% -$127M
$376K
Interest Expense
—
Interest Income↓-1.3% -$92K
$7M
Other Income/Expense↓-76.6% -$108K
$33K
Pretax Income↓-17.0% -$6M
$-39M
Tax Provision↓-66.5% -$1M
$666K
Net Income↓-18.5% -$6M
$-39M
Operating Margin↓-98.5pts
-985.2%
Net Margin↓-124.5pts
-834.9%
Effective Tax Rate↓-1.2pts
0.0%
Deferred Tax Assets
—
ETR (Continuing Operations)↓-2.1pts
-0.6%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-0.7pts
-0.6%
ETR Foreign Differential (pp)
—
Operating Lease Cost↓-39.7% -$151K
$229K
Revenue YoY Variation↓-280.0pts
-95.6%
Income YoY Variation↓-3.8pts
-12.0%
Revenue QoQ Variation↓-3492.2pts
57.8%
Income QoQ Variation↓-3.6pts
-10.4%